Base de dados : MEDLINE
Pesquisa : D12.125.070.950 [Categoria DeCS]
Referências encontradas : 12806 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1281 ir para página                         

  1 / 12806 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29338466
[Au] Autor:Sarva H; Henchcliffe C
[Ad] Endereço:a Parkinson's Disease and Movement Disorders Institute , Weill Cornell Medicine/New York Presbyterian Hospital , New York , NY , USA.
[Ti] Título:Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
[So] Source:Expert Rev Clin Pharmacol;11(3):209-217, 2018 Mar.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Valbenazine is a selective VMAT2 inhibitor that the FDA approved in April 2017 for the specific treatment of tardive dyskinesia (TD), a movement disorder commonly caused by dopamine blocking agents. Valbenazine acts to decrease dopamine release, reducing excessive movement found in TD. Areas covered: This drug profile reviews the development of valbenazine and the clinical trials that led to its approval as the first treatment specific to TD. The literature search was performed with the PubMed online database. Expert commentary: Two clinical trials assessing the efficacy of valbenazine have shown the reduction of antipsychotic-induced involuntary movement. No life threatening adverse effects were found. Data from a 42-week extension study demonstrated sustained response.
[Mh] Termos MeSH primário: Dopamina/metabolismo
Discinesia Tardia/tratamento farmacológico
Tetrabenazina/análogos & derivados
Valina/análogos & derivados
[Mh] Termos MeSH secundário: Adulto
Animais
Antipsicóticos/administração & dosagem
Antipsicóticos/efeitos adversos
Antipsicóticos/farmacologia
Aprovação de Drogas
Seres Humanos
Discinesia Tardia/induzido quimicamente
Tetrabenazina/efeitos adversos
Tetrabenazina/farmacologia
Tetrabenazina/uso terapêutico
Valina/efeitos adversos
Valina/farmacologia
Valina/uso terapêutico
Proteínas Vesiculares de Transporte de Monoamina/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (SLC18A2 protein, human); 0 (Vesicular Monoamine Transport Proteins); 54K37P50KH (valbenazine); HG18B9YRS7 (Valine); VTD58H1Z2X (Dopamine); Z9O08YRN8O (Tetrabenazine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2018.1429264


  2 / 12806 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29338047
[Au] Autor:Hsia HP; Yang YH; Szeto WC; Nilsson BE; Lo CY; Ng AK; Fodor E; Shaw PC
[Ad] Endereço:Centre for Protein Science and Crystallography, School of Life Sciences, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.
[Ti] Título:Amino acid substitutions affecting aspartic acid 605 and valine 606 decrease the interaction strength between the influenza virus RNA polymerase PB2 '627' domain and the viral nucleoprotein.
[So] Source:PLoS One;13(1):e0191226, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The influenza virus RNA genome is transcribed and replicated in the context of the viral ribonucleoprotein (vRNP) complex by the viral RNA polymerase. The nucleoprotein (NP) is the structural component of the vRNP providing a scaffold for the viral RNA. In the vRNP as well as during transcription and replication the viral polymerase interacts with NP but it is unclear which parts of the polymerase and NP mediate these interactions. Previously the C-terminal '627' domain (amino acids 538-693) of PB2 was shown to interact with NP. Here we report that a fragment encompassing amino acids 146-185 of NP is sufficient to mediate this interaction. Using NMR chemical shift perturbation assays we show that amino acid region 601 to 607 of the PB2 '627' domain interacts with this fragment of NP. Substitutions of these PB2 amino acids resulted in diminished RNP activity and surface plasmon resonance assays showed that amino acids D605 was essential for the interaction with NP and V606 may also play a partial role in the interaction. Collectively these results reveal a possible interaction surface between NP and the PB2 subunit of the RNA polymerase complex.
[Mh] Termos MeSH primário: Vírus da Influenza A Subtipo H5N1/química
Vírus da Influenza A Subtipo H5N1/genética
RNA Replicase/química
RNA Replicase/genética
Proteínas de Ligação a RNA/química
Proteínas de Ligação a RNA/genética
Proteínas do Core Viral/química
Proteínas do Core Viral/genética
Proteínas Virais/química
Proteínas Virais/genética
[Mh] Termos MeSH secundário: Substituição de Aminoácidos
Ácido Aspártico/química
Genoma Viral
Células HEK293
Seres Humanos
Vírus da Influenza A Subtipo H5N1/fisiologia
Influenza Humana/virologia
Modelos Moleculares
Ressonância Magnética Nuclear Biomolecular
Domínios e Motivos de Interação entre Proteínas
Proteínas Recombinantes/química
Proteínas Recombinantes/genética
Ressonância de Plasmônio de Superfície
Valina/química
Replicação Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (NP protein, Influenza A virus); 0 (PB2 protein, Influenzavirus A); 0 (RNA-Binding Proteins); 0 (Recombinant Proteins); 0 (Viral Core Proteins); 0 (Viral Proteins); 30KYC7MIAI (Aspartic Acid); EC 2.7.7.48 (RNA Replicase); HG18B9YRS7 (Valine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191226


  3 / 12806 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29181548
[Au] Autor:Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
[Ad] Endereço:Hematology Department, Hospital del Mar-IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Universidad Autónoma de Barcelona, Passeig Marítim 25-29, 08003, Barcelona, Spain.
[Ti] Título:Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
[So] Source:Ann Hematol;97(3):443-451, 2018 Mar.
[Is] ISSN:1432-0584
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:JAK2V617F monitoring and NGS of non-driver genes was performed in 100 patients with polycythemia vera (PV) or essential thrombocythemia (ET) with long molecular follow-up. Patients who did not progress to myelofibrosis (MF) or acute myeloid leukemia (AML) after more than 10 years (n = 50) showed a low frequency of mutations at first sample (18%) and an incidence rate of 1.7 new mutations × 100 person-years. Mutations were detected at first sample in 83% of PV/ET patients who later progressed to AML (n = 12) with these patients having a rate of 25.6 mutations × 100 person-years. Presence of mutations at diagnosis was the unique risk factor for acquiring a new genetic event (HR 2.7, 95% CI 1.1-6.8, p = 0.03) after correction for age, PV diagnosis, and total duration of hydroxyurea (HU) exposure. Patients with additional mutation at first sample showed a higher probability of developing cytopenia under HU therapy and a higher risk of AML (HR 12.2, 95% CI 2.6-57.1, p = 0.001) with mutations in ASXL1 (p < 0.0001), TP53 (p = 0.01), SRSF2 (p < 0.0001), IDH1/2 (p < 0.0001), and RUNX1 (p < 0.0001) being associated with a higher probability of AML. Myelofibrotic transformation was more frequent in patients with additional mutations, especially in SF3B1 (p = 0.02) and IDH1/2 (p < 0.0001) although a persistently high or a progressive increase of the JAK2V617F allele burden while receiving cytoreduction was the strongest predictor of MF transformation (HR 10.8, 95% CI 2.4-49.1, p = 0.002). In conclusion, NGS may be useful to identify a minority of PV and ET patients with high genetic instability and increased risk of AML transformation.
[Mh] Termos MeSH primário: Transformação Celular Neoplásica/genética
Janus Quinase 2/genética
Mutação de Sentido Incorreto
Policitemia Vera/genética
Trombocitemia Essencial/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Alelos
Substituição de Aminoácidos
Análise Citogenética
Progressão da Doença
Feminino
Seguimentos
Frequência do Gene
Seres Humanos
Masculino
Meia-Idade
Fenilalanina/genética
Policitemia Vera/patologia
Trombocitemia Essencial/patologia
Valina/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
47E5O17Y3R (Phenylalanine); EC 2.7.10.2 (JAK2 protein, human); EC 2.7.10.2 (Janus Kinase 2); HG18B9YRS7 (Valine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1007/s00277-017-3193-5


  4 / 12806 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27775336
[Au] Autor:Zercher B; Hopkins TA
[Ad] Endereço:Department of Chemistry, Butler University , 4600 Sunset Avenue, Indianapolis, Indiana 46208, United States.
[Ti] Título:Induction of Circularly Polarized Luminescence from Europium by Amino Acid Based Ionic Liquids.
[So] Source:Inorg Chem;55(21):10899-10906, 2016 Nov 07.
[Is] ISSN:1520-510X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Materials that emit circularly polarized light have application in several important industries. Because they show large optical activity and emit sharp visible light transitions, europium complexes are often exploited in applications that require circularly polarized luminescence (CPL). Chiral and coordinating ionic liquids based on prolinate, valinate, and aspartate anions are used to induce CPL from a simple achiral europium triflate salt. The sign of the induced CPL is dependent on the handedness (l vs d) of the amino acid anion. Comparison of the CPL spectra in ionic liquid with proline and valine vs aspartate shows that the number of carboxylate groups in the amino acid anion influences the europium coordination environment. DFT calculations predict a chiral eight-coordinate Eu(Pro) structure in the prolinate ionic liquid and a chiral seven- or eight-coordinate Eu(Asp) structure in the aspartate ionic liquid.
[Mh] Termos MeSH primário: Aminoácidos/química
Európio/química
Líquidos Iônicos/química
Substâncias Luminescentes/química
Mesilatos/química
[Mh] Termos MeSH secundário: Ácido Aspártico/química
Complexos de Coordenação/química
Luminescência
Medições Luminescentes
Modelos Moleculares
Prolina/química
Valina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acids); 0 (Coordination Complexes); 0 (Ionic Liquids); 0 (Luminescent Agents); 0 (Mesylates); 30KYC7MIAI (Aspartic Acid); 444W947O8O (Europium); 9DLQ4CIU6V (Proline); HG18B9YRS7 (Valine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  5 / 12806 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190268
[Au] Autor:Tapp L; Ramsey JG; Wen A; Gerona R
[Ti] Título:Synthetic Cannabinoid and Mitragynine Exposure of Law Enforcement Agents During the Raid of an Illegal Laboratory - Nevada, 2014.
[So] Source:MMWR Morb Mortal Wkly Rep;66(47):1291-1294, 2017 Dec 01.
[Is] ISSN:1545-861X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Synthetic cannabinoids (SCs), commonly known by the street name "Spice," are designer drugs of abuse that mimic the psychoactive effects of marijuana. Intentional SC use has resulted in multiple toxicities (1,2), but little is known about occupational SC exposure. After a federal agency's law enforcement personnel in Nevada reported irritability and feeling "high" after raiding illegal SC laboratories and processing seized SCs, a request for a health hazard evaluation was made by the agency to CDC's National Institute for Occupational Safety and Health (NIOSH) in 2014 to evaluate agents' occupational SC exposures. After making the request for a health hazard evaluation, federal agents conducted a raid of an illegal SC laboratory, with assistance from local law enforcement and Drug Enforcement Administration (DEA) personnel and with NIOSH investigators observing from a distance. After the raid, agents collected and processed material evidence. NIOSH investigators tested agents' urine for SC levels before and after the raid and measured SCs in the air and on surfaces after the raid. DEA determined that AB-PINACA (an SC compound) and mitragynine (a plant material with opium-like effects, also known as "kratom") were present in the illegal laboratory. AB-PINACA, its metabolites, and mitragynine were not detected in agents' urine before the raid; however, one or more of these substances was found in the urine of six of nine agents after the raid and processing of the SC evidence. AB-PINACA was detected in one surface wipe sample from the SC laboratory; none was detected in the air in the laboratory or in the offices of the law enforcement agency where the materials were processed after the raid. No policies were in place regarding work practices and use of personal protective equipment (PPE) during raids and evidence processing. To protect agents from SC exposures, NIOSH recommended that the agency require agents to wear a minimum level of PPE (e.g., protective gloves and disposable clothing) and undergo training in PPE and in handling and storing of contaminated evidence from SC laboratory raids. Showers and locker rooms also need to be provided so that agents can reduce contamination and prevent take-home exposure.
[Mh] Termos MeSH primário: Canabinoides/urina
Drogas Desenhadas
Controle de Medicamentos e Entorpecentes/legislação & jurisprudência
Laboratórios/legislação & jurisprudência
Aplicação da Lei
Exposição Ocupacional/análise
Alcaloides de Triptamina e Secologanina/urina
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Indazóis/urina
Masculino
Meia-Idade
Nevada
Equipamento de Proteção Individual/utilização
Valina/análogos & derivados
Valina/urina
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cannabinoids); 0 (Designer Drugs); 0 (Indazoles); 0 (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide); 0 (Secologanin Tryptamine Alkaloids); EP479K822J (mitragynine); HG18B9YRS7 (Valine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180119
[Lr] Data última revisão:
180119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.15585/mmwr.mm6647a3


  6 / 12806 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779348
[Au] Autor:Lange T; Ko CW; Lai PH; Dacko M; Tsai SY; Buechert M
[Ad] Endereço:Department of Radiology, Medical Physics, Medical Center-University of Freiburg, Freiburg, Germany.
[Ti] Título:Simultaneous detection of valine and lactate using MEGA-PRESS editing in pyogenic brain abscess.
[So] Source:NMR Biomed;29(12):1739-1747, 2016 Dec.
[Is] ISSN:1099-1492
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Valine and lactate have been recognized as important metabolic markers to diagnose brain abscess by means of MRS. However, in vivo unambiguous detection and quantification is hampered by macromolecular contamination. In this work, MEGA-PRESS difference editing of valine and lactate is proposed. The method is validated in vitro and applied for quantitative in vivo experiments in one healthy subject and two brain abscess patients. It is demonstrated that with this technique the overlapping lipid signal can be reduced by more than an order of magnitude and thus the robustness of valine and lactate detection in vivo can be enhanced. Quantification of the two abscess MEGA-PRESS spectra yielded valine/lactate concentration ratios of 0.10 and 0.27. These ratios agreed with the concentration ratios determined from concomitantly acquired short-T PRESS data and were in line with literature values. The quantification accuracy of lactate (as measured with Cramér-Rao lower bounds in LCModel processing) was better for MEGA-PRESS than for short-T PRESS in all acquired in vivo datasets. The Cramér-Rao lower bounds of valine were only better for MEGA-PRESS in one of the two abscess cases, while in the other case coediting of isoleucine confounded the quantification in the MEGA-PRESS analysis. MEGA-PRESS and short-T PRESS should be combined for unambiguous quantification of amino acids in abscess measurements. Simultaneous valine/lactate MEGA-PRESS editing might benefit the distinction of brain abscesses from tumors, and further categorization of bacteria with reasonable sensitivity and specificity.
[Mh] Termos MeSH primário: Abscesso Encefálico/metabolismo
Encéfalo/metabolismo
Ácido Láctico/metabolismo
Espectroscopia de Ressonância Magnética/métodos
Imagem Molecular/métodos
Processamento de Sinais Assistido por Computador
Valina/metabolismo
[Mh] Termos MeSH secundário: Algoritmos
Biomarcadores/metabolismo
Encéfalo/patologia
Abscesso Encefálico/patologia
Seres Humanos
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 33X04XA5AT (Lactic Acid); HG18B9YRS7 (Valine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1002/nbm.3660


  7 / 12806 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773389
[Au] Autor:Doi T; Asada A; Takeda A; Tagami T; Katagi M; Kamata H; Sawabe Y
[Ad] Endereço:Department of Food, Drugs and Environment, Osaka Prefectural Institute of Public Health, 1-3-69 Nakamichi, Higashinari-ku, Osaka 537-0025, Japan. Electronic address: tdoi@iph.pref.osaka.jp.
[Ti] Título:Enantioseparation of the carboxamide-type synthetic cannabinoids N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide and methyl [1-(5-fluoropentyl)-1H-indazole-3-carbonyl]-valinate in illicit herbal products.
[So] Source:J Chromatogr A;1473:83-89, 2016 Nov 18.
[Is] ISSN:1873-3778
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Synthetic cannabinoids, recently used as alternatives to Cannabis sativa, are among the most frequently abused drugs. Identified in 2014, the synthetic cannabinoids N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AB-PINACA) and methyl [1-(5-fluoropentyl)-1H-indazole-3-carbonyl]-valinate (5F-AMB) are carboxamides composed of 1-(5-fluoropentyl)-1H-indazole-3-carboxylic acid and valine amide/methyl ester. Because of their composition, these molecules have pairs of enantiomers derived from the chiral center of their amino acid structures. Previous studies on the identification of 5F-AB-PINACA and 5F-AMB did not consider the existence of enantiomers, and there have been no reports on the enantiopurities of synthetic cannabinoids. We synthesized both enantiomers of these compounds and then separated the enantiomers by liquid chromatography-high-resolution mass spectrometry using a column with a chiral stationary phase consisted with amylose tris (3-chloro-4-methylphenylcarbamate). Under the optimized conditions, the enantiomer resolutions were 2.2 and 2.3 for 5F-AB-PINACA and 5F-AMB, respectively. Analysis of 10 herbal samples containing 5F-AB-PINACA and one herbal sample containing 5F-AMB showed that they all contained the (S)-enantiomer, but the (R)-enantiomer was only detected in two samples and at a ratio of less than 20%.
[Mh] Termos MeSH primário: Canabinoides/isolamento & purificação
Cromatografia Líquida
Indazóis/isolamento & purificação
Espectrometria de Massas
Preparações de Plantas/química
Valina/análogos & derivados
[Mh] Termos MeSH secundário: Canabinoides/análise
Canabinoides/química
Indazóis/análise
Indazóis/química
Valina/análise
Valina/química
Valina/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cannabinoids); 0 (Indazoles); 0 (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); 0 (Plant Preparations); 0 (methyl (1-(5-fluoropentyl)-1H-indazole-3-carbonyl)valinate); HG18B9YRS7 (Valine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  8 / 12806 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27777201
[Au] Autor:Cui JZ; Zhang JW; Zhang Y; Ma ZL
[Ad] Endereço:Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, China. E-mail: cuijizheng@126.com.
[Ti] Título:[Efficacy of intracutaneous methylene blue injection for moderate to severe acute thoracic herpes zoster pain and prevention of postherpetic neuralgia in elderly patients].
[So] Source:Nan Fang Yi Ke Da Xue Xue Bao;36(10):1377-1381, 2016 Oct 20.
[Is] ISSN:1673-4254
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To evaluate the clinical efficacy of intradermal injection of methylene blue for treatment of moderate to severe acute thoracic herpes zoster and prevention of postherpetica neuralgia in elderly patients. METHODS: Sixty-four elderly patients with herpes zoster were randomized to receive a 10-day course of intradermal injection of methylene blue and lidocaine plus oral valaciclovir (group A, 32 cases) and intradermal injection of lidocaine plus oral valaciclovir (group B).Herpes evaluation index, pain rating index, incidence of postherpetic neuralgia, and comprehensive therapeutic effect were compared between the two groups at 11, 30 and 60 days after the treatment. RESULTS: The baseline characteristics were comparable between the two groups (all P>0.05). Compared with that in group B, the time for no new blister formation, blister incrustation and decrustation, and pain relief was significantly shortened in group A (P<0.05) with also obviously lower pain intensity after the treatment. The incidence of postherpetic neuralgia was significantly lower in group A than in group B at 30 days (P<0.05), but not at 60 and 90 days after the treatment. The total clinical response rate was 93.8% in group A, much higher than that in group B (62.5%, P<0.05). CONCLUSION: Intradermal injection of methylene blue can effectively shorten the disease course, reduce the pain intensity and prevent the development of postherpetic neuralgia in elderly patients with herpes zoster.
[Mh] Termos MeSH primário: Herpes Zoster/complicações
Azul de Metileno/administração & dosagem
Neuralgia Pós-Herpética/terapia
[Mh] Termos MeSH secundário: Aciclovir/administração & dosagem
Aciclovir/análogos & derivados
Aciclovir/uso terapêutico
Idoso
Seres Humanos
Incidência
Injeções Intradérmicas
Lidocaína/administração & dosagem
Lidocaína/uso terapêutico
Azul de Metileno/uso terapêutico
Medição da Dor
Valina/administração & dosagem
Valina/análogos & derivados
Valina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
98PI200987 (Lidocaine); HG18B9YRS7 (Valine); MZ1IW7Q79D (valacyclovir); T42P99266K (Methylene Blue); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  9 / 12806 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28863861
[Au] Autor:Palterer B; Brugnolo F; Sieni E; Barilaro A; Parronchi P
[Ad] Endereço:Department of Clinical and Experimental Medicine, Unit of Internal Medicine, University of Florence, Italy. Electronic address: boaz.palterer@unifi.it.
[Ti] Título:Neuromyelitis optica, atypical hemophagocytic lymphohistiocytosis and heterozygous perforin A91V mutation.
[So] Source:J Neuroimmunol;311:10-13, 2017 Oct 15.
[Is] ISSN:1872-8421
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Neuromyelitis optica is an autoimmune demyelinating inflammatory disease characterized by optic neuritis and myelitis with anti-aquaporin 4 antibodies. Hemophagocytic lymphohistiocytosis is a severe systemic inflammatory syndrome that can present in a genetic primary form or secondarily to infective, neoplastic or autoimmune diseases. Our case discusses the first reported case of atypical late-onset hemophagocytic lymphohistiocytosis in a patient with neuromyelitis optica, with multiple triggering factors and carrying the common A91V hypomorphic perforin mutation, that blurs the distinction between primary and secondary forms.
[Mh] Termos MeSH primário: Linfo-Histiocitose Hemofagocítica/genética
Mutação/genética
Neuromielite Óptica/genética
Perforina/genética
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Alanina/genética
Antígenos CD/metabolismo
Seres Humanos
Linfócitos/efeitos dos fármacos
Linfócitos/patologia
Linfo-Histiocitose Hemofagocítica/complicações
Linfo-Histiocitose Hemofagocítica/diagnóstico por imagem
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Neuromielite Óptica/complicações
Neuromielite Óptica/diagnóstico por imagem
Neuromielite Óptica/tratamento farmacológico
Medula Espinal/diagnóstico por imagem
Valina/genética
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Antigens, CD); 126465-35-8 (Perforin); HG18B9YRS7 (Valine); OF5P57N2ZX (Alanine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170903
[St] Status:MEDLINE


  10 / 12806 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28851624
[Au] Autor:Khan SH; Islam A; Hassan MI; Sharma S; Singh TP; Ahmad F
[Ad] Endereço:Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India.
[Ti] Título:Effect of conservative mutations (L94V and L94I) on the structure and stability of horse cytochrome c.
[So] Source:Arch Biochem Biophys;633:40-49, 2017 Nov 01.
[Is] ISSN:1096-0384
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A sequence alignment of horse cytochrome c (cyt c) with all known cyts c shows that Leu at position 94 is conserved, except in 14 species which have either Val or Ile at this position. It is also known that Leu94 of the mammalian cyt c plays an important role in folding and stability. The important question here is as to what will happen in terms of folding and stability if Leu94 of the mammalian cyt c is substituted by Val or Ile. To answer this question, we introduced natural substitutes of Leu94 by Val and Ile in horse cyt c. The purified L94V and L94I mutants under native condition (pH 6.0, 25 °C) were characterized using far-UV, near-UV and Soret- circular dichroism, visible absorbance, Trp and ANS (1-anilino-8-napthaline sulphonate) fluorescence and dynamic light scattering measurements. Furthermore, stability parameters T (mid-point of denaturation) and ΔG (Gibbs free energy change at 25 °C) were also determined using spectroscopic and differential scanning calorimetric methods. All these measurements led us to conclude that both mutants exist as molten globule and are less stable than the wild-type protein. These observations are supported well by examining the structure of horse cyt c (PDB ID, 1HRC).
[Mh] Termos MeSH primário: Citocromos c/química
Isoleucina/química
Leucina/química
Mutação
Valina/química
[Mh] Termos MeSH secundário: Motivos de Aminoácidos
Substituição de Aminoácidos
Animais
Sítios de Ligação
Clonagem Molecular
Citocromos c/genética
Citocromos c/metabolismo
Estabilidade Enzimática
Escherichia coli/genética
Escherichia coli/metabolismo
Expressão Gênica
Cavalos
Isoleucina/metabolismo
Cinética
Leucina/metabolismo
Ligação Proteica
Domínios e Motivos de Interação entre Proteínas
Estrutura Secundária de Proteína
Estrutura Terciária de Proteína
Proteínas Recombinantes/química
Proteínas Recombinantes/genética
Proteínas Recombinantes/metabolismo
Especificidade por Substrato
Termodinâmica
Valina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Recombinant Proteins); 04Y7590D77 (Isoleucine); 9007-43-6 (Cytochromes c); GMW67QNF9C (Leucine); HG18B9YRS7 (Valine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170831
[St] Status:MEDLINE



página 1 de 1281 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde